UnitedHealth Group Incorporated · UNH · FY2026 Q1 · Calendar Q2 2026

UnitedHealth beats Q1 with EPS $7.23, reaffirms 2026 outlook above $18.25 as all segments beat plan

UnitedHealth delivered a clean beat in Q1 2026 - adjusted EPS of $7.23 (+11.9% vs consensus) on revenue of $112.0bn (+2.4% YoY) - with all four segments ahead of plan. The near-term story is margin recovery rather than membership volume: management is leaning on repricing, AI-enabled cost efficiencies (~$1.5bn AI investment targeting a 2:1 ROI), and digital engagement while guiding membership down about 1.3 million for the year. That balanced narrative - a beat today, deliberately shrinking volumes ahead, and FY2026 EPS reaffirmed above $18.25 - supports continued earnings growth, but it hinges on medical cost trends (MA trend ~7-8% vs ~10% pricing) staying contained and on regulators not moving the goalposts on Medicare Advantage rates or PBM rules.

Why did UNH rise 7.0% after beating EPS estimates in FY2026 Q1?

Research this report with FN2. Free to start; review your question before sending.

Reported Before market openNYSEHealthcare $340.56B market cap
100quality score

Earnings scorecard

Reported versus consensus
Reported EPS $7.23 Consensus $6.46
EPS surprise +11.9% Reported versus consensus
Reported revenue $112.03B Consensus $109.43B
Revenue surprise +2.4% Reported versus consensus
Check the math in the surprise calculator >

Market reaction

prior-close to event-session close
Stock move +7.0% Event window
SPY move -0.7% Same window
Abnormal move +7.6% Stock minus SPY
Volume 3.2× Versus trailing sessions
Subsequent drift +12.5% Up to 20 sessions
UNHSPY benchmark

Ask FN2 about UNH FY2026 Q1

Choose a question to continue your research

Free to start. Your question opens in chat for you to review and send. FN2 can look up the transcript, financials and prior quarters.

Transcript intelligence

What changed

Q1 2026 was the first earnings update since UNH raised its 2026 outlook in the prior quarter. The company beat consensus on both adjusted EPS ($7.23 vs $6.46 expected, +11.9%) and revenue ($112.0bn vs $109.4bn), with all segments ahead of plan. Guidance was maintained rather than raised - FY2026 adjusted EPS reaffirmed above $18.25 - while capital deployment ratcheted up: $2bn of share repurchases targeted by end of Q2, sale of the U.K. business for $525m (with $400m to the United Health Foundation), the Alegeus Technologies acquisition (accretive in 2027), and a $1.5bn AI investment program.

Guidance delta

Maintained. Management reaffirmed FY2026 adjusted EPS above $18.25, after raising it to above $17.75 (at least 8.6% growth) in the prior quarter. The market rewarded the reaffirmation and the beat: the stock moved an abnormal +7.6% on the report session versus a -0.7% benchmark, and subsequently drifted roughly +12.5% higher in the weeks after.

Key takeaways

  • All operating segments exceeded Q1 plan, with UnitedHealthcare pricing improvements and Optum Health operational gains.
  • FY2026 adjusted EPS guidance reaffirmed above $18.25, with $2bn of share repurchases targeted by end of Q2.
  • Membership is expected to decline about 1.3 million in 2026 (roughly one-third total decline vs prior year), with growth to come from margin recovery rather than volume.
  • AI and digital tools are scaling: 73m digital visits and 95% of prior authorizations submitted electronically, with a $1.5bn AI investment targeting a 2:1 ROI.
  • Portfolio moves: U.K. business sold for $525m; Alegeus Technologies acquisition expected accretive in 2027.

Management priorities

  • Deploy AI across core processes targeting a 2:1 ROI and commercialize AI solutions externally.
  • Expand rural hospital payment acceleration by 50% and build network partnerships with regional health systems.
  • Scale digital tools including the Avery AI chatbot and digital prior authorization.
  • Complete the Alegeus Technologies acquisition and integrate it into Optum Financial Services.
  • Continue share repurchases, targeting $2bn by end of Q2.

Follow UNH with an agent that reads every filing, transcript, and price print. Free to start.

Try FN2 free

Earnings History

Estimate Beat Miss Match
UNH REVENUE earnings history estimate and actual scatter chart 10 reported fiscal quarters and 4 future estimate-only quarters. Q4 '23 estimate $92B Q4 '23 actual $93B, beat Q1 '24 estimate $99B Q1 '24 actual $99B, miss Q2 '24 estimate $99B Q2 '24 actual $98B, miss Q3 '24 estimate $99B Q3 '24 actual $103B, beat Q2 '25 estimate $112B Q2 '25 actual $112B, match Q3 '25 estimate $113B Q3 '25 actual $113B, beat Q4 '25 estimate $114B Q4 '25 actual $113B, miss Q1 '26 estimate $109B Q1 '26 actual $112B, beat Q2 '26 estimate $111B Q2 '26 actual $112B, beat Q3 '26 estimate $111B Q3 '26 actual $113B, beat Q4 '26 estimate $112B Q1 '27 estimate $114B Q2 '27 estimate $115B Q3 '27 estimate $117B
Show less

Analyst Consensus ?

ConsensusBuy52 ratings
Bullish4382.7%
Neutral713.5%
Bearish23.8%

Analyst 52W Price Targets

$339.85Current
$327Low
$492.92Average
$650High

Latest persisted target per named analyst; persisted current price from FN2's market snapshot as of Nov 22, 2026. Not an FN2 forecast.

Firm-level rating actions

FMP grade actions identify the grading firm, not a named analyst.

FirmRatingPrior ratingActionDate
Wells Fargo Overweight OverweightMaintainOct 27, 2026
Morgan Stanley Overweight OverweightMaintainOct 27, 2026
Mizuho Outperform OutperformMaintainOct 22, 2026
RBC Capital Outperform OutperformMaintainOct 20, 2026
JP Morgan Overweight OverweightMaintainOct 16, 2026
Show 47 more rating actions

Named analyst price targets

Upside is calculated against the persisted current price $339.85. FMP does not supply a rating on these named-analyst rows.

FirmAnalyst52W targetPrice when postedUpsideDate
TD CowenRyan Langston$455$330.48 +33.9%Nov 20, 2026
Morgan StanleyAnalyst unavailable$531$410.7 +56.2%Oct 27, 2026
Wells FargoStephen Baxter$487$410.7 +43.3%Oct 27, 2026
Mizuho SecuritiesAnalyst unavailable$500$417 +47.1%Oct 22, 2026
RBC CapitalBen Hendrix$498$406.88 +46.5%Oct 20, 2026
See 137 more

Track every rating change on UNH the moment it posts. Free to start.

Start free

Company context

Snapshot as of publication

UnitedHealth Group Incorporated (UNH) operates as a comprehensive healthcare enterprise across the United States, structuring its diverse services into four key divisions: UnitedHealthcare, Optum Health, Optum Insight, and Optum Rx. The UnitedHealthcare segment provides a wide array of health benefit plans and consumer-focused services. These offerings cater to a broad spectrum of clients, including large national corporations, public sector employers, mid-sized and small businesses, and individual consumers. It also delivers specialized health coverage and wellness programs tailored for individuals aged 50 and older, addressing their needs for preventive and acute care, chronic disease management, and other age-specific health issues. This division further encompasses Medicaid plans, children's health insurance, dental benefits, and various hospital and clinical services. Optum Health focuses on delivering direct healthcare solutions and management services.…

Historical context

All UNH earnings

Healthcare peers this season

Latest reports in the same sector
CompanyQuarterEPS surpriseMarket moveHeadline
ASND Ascendis Pharma A/S FY2026 Q3 · Calendar Q4 2026 +38.7% +3.0% Ascendis Q3 growth broadens the story, while execution risks remain
ALC Alcon Inc. FY2026 Q3 · Calendar Q4 2026 +2.2% -2.3% Alcon holds FY outlook as new launches meet IOL competition

Latest beats and misses

Who reports next

Get the UNH recap when the next report posts

One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.

Sources

  1. Earnings call transcript and parsed analysis · 2026-05-11T10:29:34.698584+00:00
  2. FN2 earnings calendar · 2026-07-26T00:37:12.209961+00:00
  3. Polygon adjusted daily market bars · 2026-09-25T14:41:14.875039+00:00
  4. Financial Modeling Prep analyst price-target consensus and quote snapshot · 2026-09-25T14:41:14.872228+00:00

Methodology

Reported and consensus figures come from FN2's earnings event records. Market reaction and volume are calculated from daily adjusted bars around the event; abnormal move subtracts the SPY move over the same window.

Analyst target low, average, and high values are derived at request time from each named analyst's latest persisted FMP target. The current-price marker comes from FN2's persisted market snapshot. They are sell-side estimates, not an FN2 valuation or recommendation.

Transcript intelligence is a structured synthesis of the current and prior earnings-call analyses. Missing values stay missing and are never estimated.

By FN2 Research · Updated · As of 2026-09-25. For educational purposes only; not investment advice.